Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

The overall lifetime risk of heart failure (HF) is similar between men and women, however,
there are marked sex differences in the landscape of this condition that are both important …

Inflammation plays a prominent role in the development of atherosclerosis and other
cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular …

Background In cardiovascular disease, prevention strategies targeting standard modifiable
cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, and …

Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …

Objectives: The authors sought to evaluate the plaque-modifying effects of low-dose
colchicine therapy plus optimal medical therapy (OMT) in patients post-acute coronary …

Background Several trials have demonstrated protective effects from inhibition of sodium‐
glucose cotransporter 2 among patients with type 2 diabetes mellitus. There is uncertainty …

Aims Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits
the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly …

Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the
CANagliflozin cardioVascular Assessment Study (CANVAS) Program. This analysis …

Background: People with type 2 diabetes and chronic kidney disease experience a high
burden of hypertension, but the magnitude and consistency of blood pressure (BP) lowering …